Edward A Ratovitski
Dr. Edward Ratovitski has received his Ph.D. Degree in Molecular Biology and Cancer Biology from the Petrov Cancer Research Institute (Leningrad, USSR) in 1979. In 1990, he started working at the Weizmann Institute of Science (Rehovot, Israel), where he studied the interferon type I receptor signaling. In 1994, he joined the Johns Hopkins University School of Medicine (Baltimore, Maryland, USA), where he has developed a strong long-lasting interest in protein-protein interactions studies (e.g. MDK and NOS2). Finally he focused on the p63 transcriptional factor implicated in head and neck cancer and ectodermal dysplasia. He has discovered a molecular mechanism underlying ectodermal dysplasia via p63-dependent regulation of RNA splicing for fibroblast growth factor receptor 2, which functions as a key regulator of the epithelial-mesenchymal transition. His collaborative efforts with Drs. David Sidransky and Barry Trink led to more than 45 international publications, reviews and patents on p63 function.
cancer, ectodermal dysplasia, inflammation, molecular mechanisms of chemoresistance, signaling, protein interactions, protein modifications, transcription, splicing, microRNA, oncogenes and tumor suppressors, p53 family members, NOS2